RECRUITING

Project neuroARTEMIS

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to understand how chronic stress affects the way our brain and immune systems function, and in turn how this affects the way people feel, think, and behave. By learning more about how these processes work, the hope is to be able to develop better treatments to help with problems like depression and substance use. This study is intended for individuals that are HIV positive, currently taking prescription antiretroviral medications, and use stimulants. Through this intervention, the aim is to determine if this positive affect intervention can lead to reductions in stimulant use and depressed mood.

Official Title

Project ARTEMIS: A Mechanistic Clinical Trial of Neuroimmune Pathways.

Quick Facts

Study Start:2025-04-29
Study Completion:2028-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06814275

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 59 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18-59 years old
  2. * Weekly use of stimulants reported in the past month or a score of 4 or more on the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
  3. * Confirmed HIV diagnosis
  4. * Current receipt of daily oral antiretroviral therapy (ART) medication
  5. * English fluency/literacy
  1. * Acute brain infection (e.g., neurosyphilis, toxoplasmosis)
  2. * Acutely symptomatic bipolar I or psychotic disorder
  3. * Prescription for immunomodulatory medications or other immunotherapy
  4. * Any MRI contraindications
  5. * If applicable, on antidepressant medication regimen for at least 2 months

Contacts and Locations

Study Contact

Christina S Meade, PhD
CONTACT
336-716-0695
cmeade@wakehealth.edu
Sheri L Towe, PhD
CONTACT
336-716-4331
stowe@wakehealth.edu

Principal Investigator

Christina S Meade, PhD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences
Adam W Carrico, PhD
PRINCIPAL_INVESTIGATOR
Florida International University

Study Locations (Sites)

Wake Forest University School of Medicine
Winston-Salem, North Carolina, 27101
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Christina S Meade, PhD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences
  • Adam W Carrico, PhD, PRINCIPAL_INVESTIGATOR, Florida International University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-29
Study Completion Date2028-12-31

Study Record Updates

Study Start Date2025-04-29
Study Completion Date2028-12-31

Terms related to this study

Keywords Provided by Researchers

  • HIV
  • Stimulant use
  • substance abuse
  • chronic stress

Additional Relevant MeSH Terms

  • Stimulant Use
  • Human Immunodeficiency Virus (HIV)
  • Depression